158 related articles for article (PubMed ID: 31446281)
21. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
[TBL] [Abstract][Full Text] [Related]
22. KLK31P is a novel androgen regulated and transcribed pseudogene of kallikreins that is expressed at lower levels in prostate cancer cells than in normal prostate cells.
Lu W; Zhou D; Glusman G; Utleg AG; White JT; Nelson PS; Vasicek TJ; Hood L; Lin B
Prostate; 2006 Jun; 66(9):936-44. PubMed ID: 16541416
[TBL] [Abstract][Full Text] [Related]
23. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
24. Compartmentalized expression of kallikrein 4 (KLK4/hK4) isoforms in prostate cancer: nuclear, cytoplasmic and secreted forms.
Dong Y; Bui LT; Odorico DM; Tan OL; Myers SA; Samaratunga H; Gardiner RA; Clements JA
Endocr Relat Cancer; 2005 Dec; 12(4):875-89. PubMed ID: 16322328
[TBL] [Abstract][Full Text] [Related]
25. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.
Tomlins SA; Mehra R; Rhodes DR; Smith LR; Roulston D; Helgeson BE; Cao X; Wei JT; Rubin MA; Shah RB; Chinnaiyan AM
Cancer Res; 2006 Apr; 66(7):3396-400. PubMed ID: 16585160
[TBL] [Abstract][Full Text] [Related]
26. Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.
Kunju LP; Carskadon S; Siddiqui J; Tomlins SA; Chinnaiyan AM; Palanisamy N
Appl Immunohistochem Mol Morphol; 2014 Sep; 22(8):e32-40. PubMed ID: 25203299
[TBL] [Abstract][Full Text] [Related]
27. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
28. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.
Xi Z; Klokk TI; Korkmaz K; Kurys P; Elbi C; Risberg B; Danielsen H; Loda M; Saatcioglu F
Cancer Res; 2004 Apr; 64(7):2365-70. PubMed ID: 15059887
[TBL] [Abstract][Full Text] [Related]
29. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
Palanisamy N; Tsodikov A; Yan W; Suleman K; Rittmaster R; Lucia SM; Chinnaiyan AM; Fleshner N; Kunju LP
Urol Oncol; 2015 Mar; 33(3):108.e5-13. PubMed ID: 25175425
[TBL] [Abstract][Full Text] [Related]
31. Genetic association of the KLK4 locus with risk of prostate cancer.
Lose F; Srinivasan S; O'Mara T; Marquart L; Chambers S; Gardiner RA; Aitken JF; ; Spurdle AB; Batra J; Clements JA
PLoS One; 2012; 7(9):e44520. PubMed ID: 22970239
[TBL] [Abstract][Full Text] [Related]
32. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
33. Analysis of fusion gene expression in prostate tumors by using single-end reads.
Xie DD; Li JY; Wang Y; Chen L; Yu DX
Genet Mol Res; 2013 Aug; 12(3):2886-94. PubMed ID: 24065644
[TBL] [Abstract][Full Text] [Related]
34. Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: implications for xenograft models of human prostate cancer.
Lisle JE; Mertens-Walker I; Stephens CR; Stansfield SH; Clements JA; Herington AC; Stephenson SA
Exp Cell Res; 2015 Apr; 333(1):136-46. PubMed ID: 25724897
[TBL] [Abstract][Full Text] [Related]
35. Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer.
Klokk TI; Kilander A; Xi Z; Waehre H; Risberg B; Danielsen HE; Saatcioglu F
Cancer Res; 2007 Jun; 67(11):5221-30. PubMed ID: 17545602
[TBL] [Abstract][Full Text] [Related]
36. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
[TBL] [Abstract][Full Text] [Related]
37. ETS factors in prostate cancer.
Qian C; Li D; Chen Y
Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
[TBL] [Abstract][Full Text] [Related]
38. Clinical applications of novel ERG immunohistochemistry in prostate cancer diagnosis and management.
Shah RB
Adv Anat Pathol; 2013 Mar; 20(2):117-24. PubMed ID: 23399797
[TBL] [Abstract][Full Text] [Related]
39. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera.
Day CH; Fanger GR; Retter MW; Hylander BL; Penetrante RB; Houghton RL; Zhang X; McNeill PD; Filho AM; Nolasco M; Badaro R; Cheever MA; Reed SG; Dillon DC; Watanabe Y
Oncogene; 2002 Oct; 21(46):7114-20. PubMed ID: 12370833
[TBL] [Abstract][Full Text] [Related]
40. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3-ERG gene rearrangement and an unfavorable clinical course.
Perner S; Rupp NJ; Braun M; Rubin MA; Moch H; Dietel M; Wernert N; Jung K; Stephan C; Kristiansen G
Int J Cancer; 2013 Feb; 132(4):807-12. PubMed ID: 22821757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
